Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: Access to antiretroviral therapy, disease progression and survival

AIDS

Volumn 17, Issue 15, 2003, Pages 2237-2244

  Staehelin, Cornelia ^a   Rickenbach, Martin ^b   Low, Nicola ^h   Egger, Martin ^a   Ledergerber, Bruno ^c   Hirschel, Bernard ^d   D'Acremont, Valérie ^e   Battegay, Manuel ⁱ   Wagels, Thomas ⁱ   Bernasconi, Enos ^f   Kopp, Christine ^g   Furrer, Hansjakob ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Swiss HIV Cohort Study Data Center   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f Cantonal Hospital Lugano   (Switzerland)

^g FEDERAL OFFICE OF PUBLIC HEALTH   (Switzerland)

^h UNIVERSITY OF BRISTOL   (United Kingdom)

ⁱ NONE

Author keywords

Africa; AIDS; CD4 cell count; Cohort studies; Disease progression; HIV; Migration; Proportional hazards models; Survival; Switzerland; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICA; AGE DISTRIBUTION; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; POPULATION MIGRATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PUBLIC HEALTH SERVICE; SEX DIFFERENCE; SEXUAL BEHAVIOR; SURVIVAL RATE; SWITZERLAND; T LYMPHOCYTE; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AFRICA SOUTH OF THE SAHARA; AGE FACTORS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; EMIGRATION AND IMMIGRATION; EUROPE; FEMALE; HEALTH SERVICES ACCESSIBILITY; HETEROSEXUALITY; HIV INFECTIONS; HIV-1; HUMANS; MALE; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 10744229012     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200310170-00012     Document Type: Article

References (30)

1. Bundesamt für Gesundheit. AIDS und HIV in der Schweiz. Epidemiologische Situation Ende 2000. Bern: Bundesamt für Gesundheit, Epidemiologie und Infektionskrankheiten; 2002.
2. Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth JA. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS 2002, 16:597-603.
3. Salamon R, Marimoutou C, Ekra D, Minga A, Nerrienet E, Huet C, et al. Clinical and biological evolution of HIV-1 seroconverters in Abidjan, Cote d'Ivoire, 1997-2000. J Acquir Immune Defic Syndr 2002, 29:149-157.
4. Anon. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe [in process citation]. Lancet 2000, 355: 1131-1137.
5. Morgan D, Mahe C, Mayanja B, Whitworth JA. Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study. BMJ 2002, 324:193-196.
6. del Amo J, Petruckevitch A, Phillips A, Johnson AM, Stephenson J, Desmond N, et al. Disease progression and survival in HIV-1-infected Africans in London. AIDS 1998, 12:1203-1209.
7. Gebhardt M, Rickenbach M, Egger M, and the Swiss HIV Cohort Study. Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland. AIDS 1998, 12:1195-1201.
8. Ledergerber B, von Overbeck J, Egger M, Lüthy R. The Swiss HIV cohort study: rationale, organization and selected baseline characteristics. Soz Präventivmed 1994, 39:387-394.
9. Sudre P, Rickenbach M, Taffé P, Janin P, Volkart AC, Francioli P, et al. Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988-2000. Schweiz Med Wochenschr 2000, 130:1493-1500.
10. Centers for Disease Control and Prevention. 1993 classification system for HIV infection and expanded surveillance case definition for acquired immunodeficiency syndrome (AIDS) among adolescents and adults. MMWR 1992, 41:1-19.
11. Piot P, Bartos M, Ghys PD, Walker N, Schwartlander B. The global impact of HIV/AIDS. Nature 2001, 410:968-973.
12. Subkommission Klinik (SKK) der Eidgenössischen Kommission für AIDS-Fragen (EKAF), Antiretrovirale Therapie, Empfehlungen 1998. Bull Bundesamts Gesund 1998, 27:5-9.
13. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280:78-86.
14. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000, 283:381-390.
15. Morgenstern H. Ecologic studies. In: Modern Epidemiology. 2nd edn. Edited by Rothman KJ, Greenland S. Philadelphia, PA: Lippincott Williams & Wilkins, 1998:459-480.
16. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119-129.
17. Barry SM, Lloyd-Owen SJ, Madge SJ, Cozzi-Lepri A, Evans AJ, Phillips AN, et al. The changing demographics of new HIV diagnoses at a London centre from 1994 to 2000. HIV Med 2002, 3:129-134.
18. Manfredi R, Calza L, Chiodo F. HIV disease among immigrants coming to Italy from outside of the European Union: a case-control study of epidemiological and clinical features. Epidemiol Infect 2001, 127:527-533.
19. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002, 288:222-235.
20. Bassetti S, Battegay M, Furrer H, Rickenbach M, Flepp M, Kaiser L, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 21:114-119.
21. Wood E, Montaner JS, Chan K, Tyndall MW, Schechter MT, Bangsberg D, et al. Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS 2002, 16:2065-2072.
22. Smith GD. Learning to live with complexity: ethnicity, socio-economic position, and health in Britain and the United States. Am J Public Health 2000, 90:1694-1698.
23. Bhopal R. Spectre of racism in health and health care: lessons from history and the United States. BMJ 1998, 316: 1970-1973.
24. Burns FM, Fakoya AO, Copas AJ, French PD. Africans in London continue to present with advanced HIV disease in the era of highly active antiretroviral therapy. AIDS 2001, 15:2453-2455.
25. Egger M, Hirschel B, Francioli P, Sudre P Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997, 315:1194-1199.
26. Palella FJ, Delaney KM, Moorman AC, Loveless AO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
27. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al. AIDS across Europe, 1994-98: the EuroSIDA study [in process citation]. Lancet 2000, 356:291-296.
28. Hogg RS, Heath KV, Yip B, Craib KJP, O'Shaughnessy MV, Schlechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998, 279:450-454.
29. Frater AJ, Dunn DT, Beardall AJ, Ariyoshi K, Clarke JR, McClure MO, et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002, 16:1139-1146.
30. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002, 359:2059-2064.